Turning Point Therapeutics Operating Income

Turning Point Therapeutics (TPTX) currently reports a operating income of $-340M as of June 2022. That compares with $-160M in the prior-year period — down 115.2% year over year. Use the charts on this page to explore Turning Point Therapeutics's operating income history and peer comparisons.

Turning Point Therapeutics's operating income decreased from $-160M to $-340M — a 115.2% year-over-year decrease (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Turning Point Therapeutics reported $-340M in operating income as of June 2022. That compares with $-160M in the prior-year period — down 115.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-340M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Turning Point Therapeutics, and consider following TPTX for alerts when major investors trade the stock.

Turning Point Therapeutics is classified in the Healthcare sector. On operating income, it currently shows $-340M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TPTX with unrelated industries.